EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A novel acridine flow cytometry marker to track post‐transfusion amustaline/glutathione pathogen‐reduced red blood cell survival in sickle cell disease patients

Richard J Benjamin iD, John P Pitman iD, Christopher Karim, Shengnan Huang, Anna Erickson, Laurence Corash iD, Nina Mufti, John D Roback, Patricia E Zerra, Ross M Fasano iD, Marianne E M Yee

Transfusion · 2025

DOI: 10.1111/trf.18245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Richard J Benjamin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cerus Corporation, Concord, California, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Flow Cytometry, Erythrocyte Transfusion, Acridines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIH/NHLBI, Biomedical Advanced Research and Development Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Measurement of transfused red blood cell (RBC) survival is relevant to the effective management of sickle cell disease (SCD). Following amustaline/glutathione pathogen‐reduced (PR) RBC transfusion, small quantities of PR‐RBC surface‐bound acridine are detectable by flow cytometry. Concurrent biotin labeling was used to validate the acridine marker and track transfused PR‐RBCs in SCD.

Methods

SCD patients ( n = 6) on chronic transfusion therapy received three aliquots of different (2 μg/mL, 6 μg/mL, and 18 μg/mL) biotin‐dose labeled RBCs during one transfusion episode. Aliquots were from one unit labeled before (Pre‐PR) and after PR treatment (PR‐RBC) and from a conventional RBC unit. The full RBC units (PR and conventional) were transfused, followed by the labeled aliquots from those units. Serial flow cytometry analyses for acridine‐ and biotin‐labeled RBCs were performed on 10 occasions over 16 weeks. Acridine surface density was quantitated using calibrated beads.

Results

Mean acridine surface density was 5062 molecules/PR‐RBC at 1–4 h post‐transfusion and declined 84.5% within 7 days, remaining detectable (180 molecules/PR‐RBC) at 16 weeks. The biotin‐labeled PR‐RBC aliquots (initial enrichment 0.6%–1.4%) demonstrated near‐identical survival kinetics as the entire acridine‐labeled PR‐RBC units (initial enrichment 7.5%–13.7%). Pre‐PR, PR, and Conventional RBCs revealed non‐linear RBC survival kinetics, with similar 24‐h post‐transfusion recoveries (PTR 24 ) and half‐lives (T 50 ), but PR‐RBC mean predicted lifespan (mean [SD] 104.4 [4.7] days) was decreased by 9.3% (Pre‐PR‐RBCs 115.1 [7.2] days, p = 0.006).

Conclusions

Survival of amustaline/glutathione PR‐RBCs can be tracked in vivo by flow cytometry for RBC surface acridine with similar sensitivity as biotin, without additional processing or radiolabeling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellFlow CytometryErythrocyte TransfusionAcridinesErythrocytesGlutathioneHumansFemaleMaleCell SurvivalAdultBiomarkers

Stichwörter der Autor:innen

RBC recovery and survivalacridineflow cytometrypathogen‐reductionred blood cells

Substanzen

AcridinesGlutathioneBiomarkers

Autor:innen und Institutionen

  • Cerus Corporation, Concord, California, USA.
  • Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Georgia Comprehensive Sickle Cell Center, Grady Health Center, Atlanta, Georgia, USA.
  • Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

ORCID-Profile: Richard J Benjamin, John P Pitman, Laurence Corash, Ross M Fasano

Förderung

  • NHLBI NIH HHS
  • NIH/NHLBI
  • Biomedical Advanced Research and Development Authority
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Benjamin, R. J., Pitman, J. P., Karim, C., Huang, S., Erickson, A., Corash, L., Mufti, N., Roback, J. D., Zerra, P. E., Fasano, R. M., & Yee, M. E. M. (2025). A novel acridine flow cytometry marker to track post‐transfusion amustaline/glutathione pathogen‐reduced red blood cell survival in sickle cell disease patients. Transfusion. https://doi.org/10.1111/trf.18245

Vancouver

Benjamin RJ, Pitman JP, Karim C, Huang S, Erickson A, Corash L, et al. A novel acridine flow cytometry marker to track post‐transfusion amustaline/glutathione pathogen‐reduced red blood cell survival in sickle cell disease patients. Transfusion. 2025. doi:10.1111/trf.18245

BibTeX
@article{Benjamin2025,
  author = {Benjamin, Richard J and Pitman, John P and Karim, Christopher and Huang, Shengnan and Erickson, Anna and Corash, Laurence and Mufti, Nina and Roback, John D and Zerra, Patricia E and Fasano, Ross M and Yee, Marianne E M},
  title = {A novel acridine flow cytometry marker to track post‐transfusion amustaline/glutathione pathogen‐reduced red blood cell survival in sickle cell disease patients},
  journal = {Transfusion},
  year = {2025},
  doi = {10.1111/trf.18245}
}
Kostenlos starten →